Group items tagged

The NHS's latest report on ambulance services in England for March 2024 reveals significant progress in response times for emergency calls across all categories compared to recent months. The Ambulance Quality Indicators (AQI) Statistical Note, released in April, underscores both improvements and persistent challenges within the sector. Recent figures obtained from the Liberal Democratic party suggest ongoing struggles with response times, particularly for category two patients, which may include individuals experiencing strokes or heart attacks requiring a response within 18 minutes. Similarly, in November last year, ambulance waits for category 2 calls surged to their highest level since December 2022, reaching 93 minutes, after dropping to 32 minutes in January 2023 according to the British Heart Foundation. However, according to the latest statistical figures obtained from AQI, March 2024 witnessed the shortest average response times for all four categories of emergency calls since August 2023.

FreeStyle Libre 3 Sensors and Budesonide 500microgram orodispersible tablets sugar free have been included in the Drugs for which Discount is Not Deducted (DND) list (Part II of the Drug Tariff) from January 2024, according to Community Pharmacy England (CPE). Following applications made by CPE on behalf of pharmacy contractors, the Department of Health and Social Care (DHSC) agreed to give DND status to these products to ensure that "pharmacies are not faced with dispensing these sensors at a loss." Updated monthly by the DHSC, Part II of the Drug Tariff includes grouped and individual items. Recently launched by Abbott Diabetes Care Ltd, FreeStyle Libre 3 Sensors have also been added to the Appliances section in Part IXA of the January 2024 Drug Tariff. As the sensors can only be ordered by pharmacies directly from the manufacturer without any discount, CPE requested the DHSC to exempt this appliance from any discount deduction.

The Department of Health and Social Care (DHSC) will introduce new arrangements for the setting of Drug Tariff Category A reimbursement prices from April 2024. Driven by ministers, DHSC's decision aims to equalise access to margin on Category A medicines and it's part of a series of drug reimbursement reforms proposed by the department following a public consultation in 2019. Currently, prices of medicines in Category A are subject to monthly adjustment. From 1 April 2024, these will be updated quarterly based on sales and volume data obtained by DHSC under the Health Service Products (Provision and Disclosure of Information) Regulations 2018. The transition will conclude in July 2025 when the reimbursement prices will be exclusively determined by the new method. Advance notice for contractors regarding the 'new arrangements' has been outlined on the NHSBSA website. However, Community Pharmacy England (CPE) did not support the introduction of the changes at this time as pharmacies are currently grappling with "wider challenges" and there is uncertainty about the potential impact of these changes on the already "turbulent" medicines supply chain

Pharmacy sales specialist, Hutchings Consultants has revealed its market predictions for the next 12 months in a new report. The broker is anticipating that both independent group operators and corporate owners will continue to reassess their existing portfolios in 2024, making strategic disposals of varying sizes. "This is likely to result in transaction volumes remaining high for the foreseeable future," stated the report authored by Paul Steet, Associate Director, Hutchings Consultants. Community Pharmacy Contractual Framework negotiations will be the most notable opportunity for the sector to capitalise upon this year, the broker said, adding that it's "a belated opportunity for the sector to secure a vital uplift to the contract's fixed global sum."

Primary Care: Endocrinology/Rheumatology/Geriatrics/Neurology is organized by American Medical Seminars and will be held from March 11 - 14, 2024, in Florida, USA

Period problems, women's health research and support for domestic and sexual abuse victims are among the government's priorities for women's health in 2024, which Health Secretary Victoria Atkins announced at the Women's Health Summit on Wednesday. Organised in central London, the event marked the second year of the landmark Women's Health Strategy for England. Victoria joined women's health champions to celebrate successes of strategy's first year and outlined plans for coming year, which also include improving maternity care and support for mothers who suffer birth trauma. Successes achieved over the strategy's first 12 months include reducing the cost of hormone replacement therapy (HRT) for nearly half a million women and the rollout of specialist women's health hubs in every local health area. A new dedicated women's health section of the NHS website was also created, providing updated information, advice and practical resources for women's health across the life course.

Pharmacy owners can make their claims for February Pharmacy First consultations until 5pm on Friday 15 March 2024, the NHS Business Services Authority (NHSBSA) announced on Monday. The deadline for Pharmacy First submission was extended following a technical issue in the NHSBSA Manage Your Service (MYS) portal, which led to the claims appearing incorrectly in the portal. The NHSBSA has been working with suppliers and NHS England to investigate and address the problem. While the problem has been resolved, the NHSBSA has advised pharmacy owners to check their submissions carefully before submitting. If any issues persist, they are advised to contact their Pharmacy First IT system supplier helpdesk to escalate the matter and not to confirm their claims in MYS until the issue has been resolved. Pharmacy owners are informed that the extended deadline is for February only and it includes any consultations completed on 31 January 2024.

AMS 2024: Internal Medicine A Review And Update-Rheumatology, Endocrinology, And Cardiology is organized by American Medical Seminars, Inc. and will be held from May 20 - 23, 2024. Clinical approach to rheumatology (Wasko) Diagnostic testing in rheumatic diseases (Wasko) Thyroid Case Studies (Winters, S) Polycystic Ovary Syndrome (Winters, S) Hypo and Hypercalcemia (Winters, S)

Professor Ryan Donnelly, esteemed for his groundbreaking contributions to pharmaceutical science, has been awarded the prestigious Royal Pharmaceutical Society (RPS) Harrison Memorial Medal for 2024. This distinguished accolade, presented in honour of the renowned pharmaceutical chemist Col EF Harrison, serves as a testament to Professor Donnelly's exceptional achievements. Currently holding the position of Chair in Pharmaceutical Technology at Queen's University Belfast's School of Pharmacy and Director of Research, Professor Donnelly has garnered acclaim for his pioneering work in developing advanced polymeric drug delivery systems. Specialising in transdermal and intradermal drug delivery methodologies, his research aims at optimising patient outcomes through innovative pharmaceutical technologies.

The global practice management system market size is expected to reach USD 17.6 billion by 2024, according to the new report

The General Pharmaceutical Council is in the process of appointing five new council members within the next two years, coinciding with the conclusion of the current members' terms. The regulator aims to recruit five individuals from diverse professional and personal backgrounds for its governing council, the GPhC has said. "We are seeking three members to join us in April 2024 and two in April 2025," said GPhC in its job advertisement brief. "For the 2024 intake, two of the new council members must be lay members of the public, while one must be a Saxton . Moreover, at least one out of the three must primarily reside or work wholly or mostly in Wales. As for the new members commencing in 2025, one must be a lay member, and the other must be a registrant member." The members will be initially appointed for a three-year term, with the option to extend their position for a maximum of eight years, GPhC added. The council, which serves as the regulator's governing body, currently comprises 14 members. Half of the council consists of lay members, who bolster public confidence and infuse novel viewpoints into the GPhC, as highlighted by the regulator. "This council will play a pivotal role in shaping the regulatory body's future strategic goals," the regulator added. "These members must contribute positively to patients and society, ensuring the benefits of secure and efficient pharmacy care."

Pharmacists on the temporary register will be automatically removed on April 1, unless they have applied to rejoin the permanent register, the General Pharmaceutical Council has said. The government asked the GPhC and other pertinent health professional regulators to close temporary registers by March 31, 2024. According to the GPhC, this decision is based on the anticipation that the emergency conditions justifying the establishment of these temporary registers will cease after the approaching winter. The temporary register was established after the Health and Social Care Secretary asked the Council to utilise its emergency powers to swiftly register pharmacy professionals for their essential role in the national COVID-19 response. Pharmacists and pharmacy technicians who had previously opted to withdraw from the GPhC register or failed to renew their registration are now eligible for immediate re-registration, the regulator added.

A new report commissioned by the National Pharmacy Association (NPA) has revealed harsh financial realities faced by community pharmacies in England. The report by Professor David Taylor of University College London warned that 1000s of community pharmacy closure might take place by 2024 in England if the sector was not supported with additional funds. At the launch of the report titled 'Protecting UK Public Interests in NHS Community Pharmacy', Prof Taylor said: "There will be several 1,000s of closures over the next few years unless we take appropriate action, which doesn't mean to pour money all over it, but it is to fund appropriately when necessary. "At the moment, if we got a partial collapse in the pharmacy network it would disrupt medicine supply and increase health inequalities… For me, it's missing out on the future development of better and more accessible care, which would be the tragedy of reducing, harming and damaging the pharmacy network unnecessarily."

The General Pharmaceutical Council (GPhC) has proposed a 7.5 per cent increase in all fees for pharmacies, pharmacists, pharmacy technicians, and foundation trainees, including those for registration and renewal from April 2024. According to the GPhC's proposal the pharmacist renewal fee would increase by £19 from £257 to £276; the pharmacy technician renewal fee would increase by £9 from £121 to £130 and the pharmacy premises renewal fee would increase by £27 from £365 to £392 Any changes would be effective from April 2024, which means fees will remain at current levels for this financial year, giving registrants and applicants time to prepare for any increase in subsequent years. Fees have been frozen for the last two years (2022 and 2023) to help reduce pressure on both pharmacy professionals and pharmacy owners. Chief Executive, Duncan Rudkin, said: "In the last few years, we have been able to avoid raising many of these fees by improving our efficiency and by using our financial reserves to cover any gap between our income and our outgoings. While we are continuing to look for ways to make savings, we now have to consider increasing fees.

AMS 2024: IMpu-Internal Medicine- Pulmonary online CME course is organized by American Medical Seminars, Inc. This conference has been approved for a maximum of 5 AMA PRA Category 1 Credits.

AMS Hospital And Internal Medicine CME Conference is organized by American Medical Seminars, Inc. and will be held from Jan 22 - 25, 2024 in Sarasota.

Community Pharmacy England (CPE) CEO, Janet Morrison said that the negotiations for the £645 million investment pledged to community pharmacies in 2023-25 have concluded. The government's primary care recovery plan is to be announced in a "few weeks" and negotiations for the Community Pharmacy Contractual Framework (CPCF) from April 2024 will begin. She said: "We have finished the substantive discussions on the recovery plan but detailed discussions about implementation are ongoing and we are awaiting final clearance from the Government and the NHS. "We hope that we will be in a position to make an announcement in the next few weeks and that negotiations on the CPCF from April 2024 will commence soon after that." Morrison reminded attendees that the Primary Care Recovery Plan is "to improve access to primary care by investing £645 million over the remainder of the year".

Duncan Rudkin, the CEO of the General Pharmaceutical Council (GPhc) has highlighted the importance of strengthening pharmacy governance to provide clarity around how pharmacies are organised and managed. This will ensure that patients and the public continue to receive safe and effective pharmacy care, he said while speaking at the annual Sigma Conference in London on Sunday (5 November). According to him, there could be rules that outlined the essential roles and responsibilities of responsible pharmacists, and professional standards for responsible pharmacists, superintended pharmacists and chief pharmacists. He also announced that the GPhC will be shortly launching a consultation to integrate a new set of standards for the statutory role of hospital chief pharmacists "which up until recently has never been recognised in law." It is expected to be launched by early January 2024. However, Duncan, emphasised that they cannot start the work on standards for responsible and superintendent pharmacists until they know the government plans in relation to supervision. "Because of course, the responsible pharmacists' regime, and the supervision regime are in many ways intertwined, and can't certainly be looked at separately.

In 2024, cannabis users will get more protection from their employers when it comes to smoking outside of work. In the meantime, here's a refresher on who can use weed - and when and where - in California. Can my employer penalize me for cannabis use? California recently passed a new cannabis bill, protecting employees from weed bias, but it will be a while before it goes into effect. Called AB 2188, it bans employers from discriminating against employees based on their use of weed off the job and away from the workplace. This includes the hiring, employment and termination processes. The law's exceptions include people working in the construction and building industry or positions that require federal background clearances. And while it protects off-duty smoking, employers will still have the right to fire or suspend employees for using weed or being high while at work. Although the bill was signed by Gov. Gavin Newsom in September, it won't be carried out until January 2024. Weed might be legal, but not for everyone Recreational cannabis use has been legal since 2016, but only for those 21 years old and over. Those under 18 who are caught with weed will be subject to drug education or counseling and community service. People who are older than 18 but under 21, will be fined up to $100. But minors can apply for a medical marijuana identification card to get weed for medicinal purposes. In California, children under 18 years old can apply as a patient if they are emancipated or have declared self-sufficiency status, according to the state's Department of Health. If they do not have this status, then the county will contact the individual's parent or legal guardian. The legal limit of weed How much cannabis you can have on hand is limited in California, according to the state's health and safety code. You'll be penalized if you possess more than 28.5 grams of weed, or more than eight grams of concentrated cannabis - essentially about one

A full CPE Committee Meeting was organised in London on April 17 and 18, 2024, to discuss crucial sectoral issues. Key topics discussed during the two-day meeting included intolerable pressures on pharmacy owners, the ongoing Community Pharmacy Contractual Framework (CPCF) negotiations, implementation of the Pharmacy First service, and governance changes. Committee Members reviewed the progress of CPCF negotiations with the Department of Health and Social Care (DHSC) and NHS England. These critical negotiations are being led by the Negotiating Team (NT), which includes independent pharmacy owners and representatives of CCA and non-CCA multiples. The CPE has been advocating for an uplift to the core global sum, margin write-offs, an agreed mechanism for regular funding increases linked to activity and inflation, annual uplifts to service fees, more fundamental reform of the margin delivery framework and an economic review of the medicines supply chain. The Committee also discussed the results of the 2024 Pharmacy Pressures Survey, which was conducted during March and April.